Becton, Dickinson and Company $BDX Shares Bought by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP lifted its holdings in Becton, Dickinson and Company (NYSE:BDX) by 10.2% in the 3rd quarter, HoldingsChannel reports. The firm owned 2,341,970 shares of the medical instruments supplier’s stock after purchasing an additional 217,716 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Becton, Dickinson and Company were worth $438,267,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. Insigneo Advisory Services LLC grew its position in Becton, Dickinson and Company by 17.1% in the 3rd quarter. Insigneo Advisory Services LLC now owns 2,907 shares of the medical instruments supplier’s stock valued at $544,000 after buying an additional 425 shares in the last quarter. Nautilus Advisors LLC bought a new position in shares of Becton, Dickinson and Company in the third quarter valued at approximately $233,000. First Eagle Investment Management LLC increased its stake in shares of Becton, Dickinson and Company by 13.8% during the third quarter. First Eagle Investment Management LLC now owns 9,994,408 shares of the medical instruments supplier’s stock valued at $1,870,653,000 after acquiring an additional 1,208,218 shares during the period. Strive Asset Management LLC bought a new stake in Becton, Dickinson and Company during the third quarter worth approximately $3,743,000. Finally, Focus Partners Advisor Solutions LLC lifted its position in Becton, Dickinson and Company by 28.8% in the third quarter. Focus Partners Advisor Solutions LLC now owns 5,798 shares of the medical instruments supplier’s stock worth $1,062,000 after purchasing an additional 1,298 shares during the period. 86.97% of the stock is currently owned by institutional investors.

Insider Transactions at Becton, Dickinson and Company

In related news, Director Bertram L. Scott sold 953 shares of the business’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $182.61, for a total value of $174,027.33. Following the completion of the sale, the director owned 36,763 shares of the company’s stock, valued at approximately $6,713,291.43. The trade was a 2.53% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Michael David Garrison sold 1,610 shares of the firm’s stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $207.46, for a total transaction of $334,010.60. Following the transaction, the executive vice president directly owned 12,095 shares in the company, valued at approximately $2,509,228.70. The trade was a 11.75% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 3,416 shares of company stock valued at $674,693 over the last ninety days. Company insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Stock Down 1.4%

Becton, Dickinson and Company stock opened at $171.80 on Thursday. Becton, Dickinson and Company has a twelve month low of $127.59 and a twelve month high of $187.35. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.58 and a current ratio of 1.05. The firm has a market cap of $48.92 billion, a PE ratio of 28.03, a P/E/G ratio of 12.63 and a beta of 0.24. The firm’s 50 day moving average price is $194.37 and its two-hundred day moving average price is $191.61.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 EPS for the quarter, beating the consensus estimate of $2.81 by $0.10. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. The business had revenue of $5.25 billion for the quarter, compared to analysts’ expectations of $5.15 billion. During the same period in the previous year, the company posted $3.43 EPS. Becton, Dickinson and Company’s revenue was up 1.6% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. On average, research analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company declared that its board has authorized a stock buyback plan on Tuesday, January 27th that authorizes the company to buyback $10.00 million in outstanding shares. This buyback authorization authorizes the medical instruments supplier to repurchase up to 0% of its stock through open market purchases. Stock buyback plans are usually an indication that the company’s board of directors believes its shares are undervalued.

Becton, Dickinson and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 31st. Shareholders of record on Tuesday, March 10th will be given a $1.05 dividend. This represents a $4.20 annualized dividend and a yield of 2.4%. The ex-dividend date of this dividend is Tuesday, March 10th. Becton, Dickinson and Company’s dividend payout ratio is presently 68.52%.

Analysts Set New Price Targets

BDX has been the topic of several research analyst reports. Zacks Research cut Becton, Dickinson and Company from a “hold” rating to a “strong sell” rating in a research report on Wednesday, February 11th. Stifel Nicolaus lifted their target price on Becton, Dickinson and Company from $210.00 to $215.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. Royal Bank Of Canada set a $172.00 price target on shares of Becton, Dickinson and Company in a report on Tuesday, February 10th. Barclays assumed coverage on shares of Becton, Dickinson and Company in a research note on Tuesday, February 10th. They issued an “overweight” rating and a $202.00 price objective on the stock. Finally, Wells Fargo & Company cut their target price on shares of Becton, Dickinson and Company from $184.00 to $157.00 and set an “equal weight” rating for the company in a research note on Tuesday, February 10th. Five research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $195.46.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.